TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Stock Price Today
Core Scientific director Elizabeth Crain buys 6,000 shares, signaling confidence in the company.
Elizabeth Crain, a director at Core Scientific, has purchased 6,000 shares of the company. This insider buying may indicate her confidence in the company's future prospects. Such moves often attract investor attention as they can signal positive expe...
Hyperscale Data shifts to AI data centers, signals undervaluation and insider confidence
Hyperscale Data has stopped Bitcoin mining to focus on AI data center services, backed by a $1.2 billion contract at its Michigan facility. The company's assets, including cash and Bitcoin, are worth nearly double its market cap, suggesting undervalu...
Affirm targets $100B GMV with diverse growth from POS, direct-to-consumer, and new products
Affirm CEO Max Levchin outlined the company's goal to reach $100 billion in annual gross merchandise volume (GMV) through a 25% growth strategy. This growth is expected to come evenly from their point-of-sale product, direct-to-consumer franchise, an...
US to ban Canadian dairy, alcohol, and motorcycles amid escalating trade dispute
The US government announced it will ban imports of Canadian dairy products, most alcoholic beverages, and motorcycles starting in three weeks. This move sharply escalates the ongoing trade dispute between the US and Canada, following Canada's recent ...
Pharvaris stock jumps after positive HAE drug trial and Oppenheimer raises price target to $75
Pharvaris's experimental oral drug deucrictibant showed an 83% reduction in hereditary angioedema (HAE) attacks in a Phase 3 trial, prompting Oppenheimer to raise its price target from $50 to $75 and maintain an "Outperform" rating. The positive tria...
Inhibrx CEO buys shares after positive cancer drug trial results, showing strong confidence.
Inhibrx Biosciences CEO Lappe Mark purchased 5,895 shares at $99.29 each following positive Phase 2 trial results for their cancer drug INBRX-106 combined with Keytruda. The trial showed a 48.3% tumor response rate, nearly double that of Keytruda alo...
Edge Total Intelligence faces $2.6M revenue loss as Austal Australia drops key contracts, prompting leadership and strategy shifts.
Edge Total Intelligence announced that Austal Australia has not renewed certain contracts under the Strategic Shipbuilding Agreement, resulting in an estimated $2.6 million revenue loss over the next year. The company is reviewing financial impacts a...
Gold miners flush with cash poised for acquisition spree as record margins boost industry growth.
Gold miners have paid off debt, increased dividends, and bought back stock, leaving them with excess cash and no leverage to reduce. The next phase in the bull market is expected to be acquisitions, with major producers likely to buy large projects f...
Marvell credits trust for 241% stock surge, securing key AI partnerships with Nvidia and Google.
Marvell Technology's CEO Matt Murphy attributes the company's 241% stock rise over the past year to a decade-long build of trust with major tech firms. This trust has enabled Marvell to secure significant AI ecosystem partnerships, including deals wi...
Nike shares hit 12-year low amid margin pressure and risk of dividend cut
Nike's stock has fallen 50% to a 12-year low, yet remains overvalued with a forward P/E of 22.36x. The company faces ongoing margin compression, declining sales, and a free cash flow payout ratio exceeding 100%, raising concerns about a potential div...
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.